Northwest Biotherapeutics (NWBO) Convertible Debt (2010 - 2026)

Northwest Biotherapeutics' Convertible Debt history runs 14 years deep, the most recent figure standing at $7.5 million for Q1 2026.

• In Q1 2026, Convertible Debt fell 42.4% year-over-year to $7.5 million; the TTM figure through Mar 2026 stood at $7.5 million (down 42.4% YoY), while the FY2025 annual figure was $5.2 million, down 67.17% from the prior year.
• Convertible Debt for Q1 2026 stood at $7.5 million, up from $5.2 million in the prior quarter.
• The five-year high for Convertible Debt was $24.6 million in Q3 2025, with the low at $3.8 million in Q3 2024.
• The 3-year median for Convertible Debt is $13.0 million (2025), against an average of $12.0 million.
• Peak annual rise in Convertible Debt reached 552.28% in 2025, while the deepest fall reached 67.17% in 2025.
• Northwest Biotherapeutics' Convertible Debt stood at $15.9 million in 2024, then sank by 67.17% to $5.2 million in 2025, then soared by 43.93% to $7.5 million in 2026.
• Business Quant data shows NWBO's Convertible Debt at $7.5 million in Q1 2026, $5.2 million in Q4 2025, and $24.6 million in Q3 2025.